Please login to the form below

Not currently logged in

ProStraken gets German approval for cancer pain drug

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral, its cancer pain drug, from the German Federal Institute for Drugs and Medical Devices (BfArM).

The company plans to launch Abstral, which was formerly branded as Rapinyl, in Germany and the UK at the beginning of 2009, and wider across Europe throughout the year.

Abstral is a fast-dissolving tablet for sub-lingual administration of fentanyl and is intended for the treatment of cancer pain in patients already receiving opioid analgesics.

Dr Wilson Totten, chief executive of ProStrakan, said: "Germany is an important market for Abstral and its approval by BfArM is a significant step forward towards its launch there. Our German operation is well advanced in its preparations for launch and we look forward to introducing German oncologists to this important product for cancer patients suffering from the debilitating effects of breakthrough pain."

ProStraken has in-licensed the exclusive rights to Abstral in Europe and North America from Orexo AB, a Swedish pharmaceutical company. The companies jointly launched the drug in Sweden in August 2008.

15th December 2008


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....